Compassion Center Calls for Media Accountability Amid Ongoing DEA Cannabis Rescheduling Hearings
Compassion Center urges media outlets to report accurately on the DEA's active cannabis rescheduling hearings, emphasizing the importance of factual coverage during this pivotal regulatory process. Suggesting that the hearing is cancelled is a lie. Misinformation like this risks undermining patient access, public trust, and informed policymaking as the DEA evaluates moving cannabis to a Schedule III substance under the Controlled Substances Act (CSA). Compassion Center remains committed to providing expert insights and advocating for patie
HILLSBORO, OREGON / ACCESS Newswire / February 19, 2025 / The Glocal Cannabis Nursing Institute (GCNI) and Compassion Center, the nation's oldest federally recognized nonprofit medical cannabis clinic system, calls upon media outlets to uphold journalistic integrity and report accurately on the Drug Enforcement Administration's (DEA) ongoing hearings regarding the potential rescheduling of cannabis to a Schedule III substance under the Controlled Substances Act (CSA).Nurse Julie Monteiro and Dr David Bearman Nurse Julie Monteiro Educating Sheriff
Despite official confirmations that the DEA hearing process is well underway, recent media reports have contained inaccuracies that risk misleading the public, policymakers, and healthcare professionals. These proceedings are a critical step in determining the future accessibility and regulation of cannabis for medical use. Misinformation surrounding this issue creates unnecessary confusion, erodes public trust, and hampers informed decision-making, while limiting the people the opportunity to stand up and make their voices heard.
'The DEA's rescheduling hearings are not speculative-they are active, documented processes with significant implications for millions of patients and providers,' stated Jason Greninger, Vice President of Legislative Advocacy for Compassion Center. 'We urge the media to verify information directly with regulatory sources, including the DEA and all other involved legal bodies, rather than relying on hearsay or incomplete accounts.'
The rescheduling process follows a structured protocol involving scientific evaluation from the U.S. Department of Health and Human Services (HHS), public commentary periods, and thorough regulatory review. Media outlets reporting premature conclusions or false facts like 'The DEA Hearing Has Been Canceled' are further misrepresenting the timeline, undermining this process and eroding all our public understandings. Compassion Center emphasizes that while no final decision has been reached, the hearings mark a pivotal point in the evolving landscape of cannabis regulation. Patients need to stand up and let their voices be heard, schedule a conference with their state and federal reps and be the change we all need to see in the world.
'Accurate information is not just a journalistic responsibility-it's a duty towards public service,' added James B. Creel, PgM, Chairman of the Board. 'Misreporting on something as consequential as cannabis scheduling could have real-world consequences for patients who depend on this medicine, as well as for healthcare providers navigating compliance issues. This is not the time to be spinning anything'
The Glocal Cannabis Nursing Institute and Compassion Center are actively engaged in these regulatory developments, advocating for patient-centered policies that ensure access to safe, effective, and affordable treatments. The organization encourages journalists to consult credible sources and avoid sensationalism that detracts from the facts at hand.
For those seeking accurate, up-to-date information on the DEA rescheduling process, Compassion Center remains available to provide expert insight and clarity.
About Compassion Center Clinics
Compassion Center is a leading integrative healthcare and mental health organization dedicated to evidence-based therapy, including medical cannabis, psychedelics, and other natural medicines. By educating providers and patients, Compassion Center is raising the standards of care, affordability, and access. Starting out as a medical cannabis clinic, today Compassion Center is the oldest federally-recognized medical management organization in the U.S. Specializing in medical cannabis clinics and psychedelic groups and retreats, expanding into integrative healthcare, mental health, prosthetics and audiology in order to bridge patients in underserved populations with a higher standard of care and an improved quality of life.
About Compassion Center, the Parent Organization
Founded in 2001, Compassion Center is the oldest federally recognized nonprofit medical cannabis clinic system in the United States, dedicated to advancing integrative healthcare, mental health, and patient advocacy. Our mission is to bridge the gap between advancing evidence-based therapies and patient-centered care, ensuring that all individuals- regardless of income, background, or diagnosis- have access to safe, effective, and affordable treatment options. That goes beyond medical cannabis recommendations, too.
For over two decades, Compassion Center has led the way in medical cannabis advocacy, education, and clinical services, integrating endocannabinology, mental health, pain management, and holistic wellness into modern healthcare. Our pop-up and in-person clinics, along with telemedicine services, ensure that patients in Oregon, 18 other states and growing, receive the highest standard of compassionate, evidence-based care.
What We Do:
Comprehensive Clinical Services - We provide integrative healthcare solutions for patients with chronic conditions, pain management needs, mental health concerns, and complex diagnoses, offering alternative therapies that go beyond conventional medicine.
Patient Advocacy & Legal Support - We fight for patients' rights by working with State legislators, government agencies, and legal professionals to ensure that medical cannabis users are protected under state and federal laws. From court-related Amicus Briefs to aiding with expert testimony in family law cases, Compassion Center is a trusted advocate for patients navigating medical and legal challenges revolving around using medical cannabis.
Interprofessional Continuing Medical Education (IPCE) - In partnership with educators at the Integrative Providers Association (IPA) and other trusted organizations, the Compassion Center educates healthcare providers on medical cannabis, alternative pain management, and integrative therapies, ensuring that today's clinicians, located all across the country are well-versed and well-equipped to serve their patients, naturally.
Innovative Programs - Compassion Center is a proud partner of TeachOneServe10.org, an initiative that turns medical education into direct patient care. Through this disruptively innovative program, licensed providers give back to underserved communities while fulfilling their continuing education requirements-helping thousands of patients at no cost.
Pioneering Research & Development - Our collaboration with the Center for Incubation & Findings Research (CIFR) and their Community-Based Clinical Cannabis Evaluation & Research Network (CBCCERN) and Glocal Cannabis Nursing Institute (GCNI), ensures that our clinical services and educational programs remain grounded in compassion, science and real-world outcomes.
Why It Matters:
Since our founding, Compassion Center has saved local taxpayers millions of dollars by reducing uncompensated care costs- while helping patients find effective, non-opioid treatment options- alleviating the strain on emergency rooms and public health systems.
By integrating research, education, and clinical services, we're not just treating diseases or their associated symptoms-we're changing the standards of care for future generations.
We are more than a clinic. We are a movement. Whether through community outreach, legislative advocacy, or cutting-edge research, Compassion Center and our group of entities and organizations are dedicated to reshaping healthcare into a more inclusive, affordable, and patient-centered system.
The Glocal Cannabis Nursing Institute (GCNI) is a global leader in cannabis nursing education, research, and patient advocacy, equipping nurses and healthcare professionals with the knowledge and tools necessary to integrate endocannabinology into evidence-based patient care. Through fellowships, interprofessional education programs, and clinical and residency training programs, GCNI empowers providers worldwide to bridge the gap between traditional medicine and cannabinoid therapeutics, ensuring safe, informed, and compassionate patient care.
844-842-COMPASSION Ext 1
Related Images
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
8 hours ago
- Associated Press
ASCP and NCPA Announce Joint Recommendations to Manufacturers to Effectuate Medicare's Maximum Fair Price (MFP)
ALEXANDRIA, VA / ACCESS Newswire / June 13, 2025 / The American Society of Consultant Pharmacists (ASCP) and the National Community Pharmacists Association (NCPA) have announced joint recommendations to pharmaceutical manufacturers aimed at helping to support pharmacies facing material cash flow concerns under Medicare's Drug Price Negotiation Program (MDPNP). The two organizations, both of which represent pharmacists committed to high-quality care for all patients including Medicare beneficiaries, expressed concerns about the impact of the MFP, which is part of the Medicare Drug Price Negotiation Program (MDPNP). This was included in the Inflation Reduction Act of 2022 and enables Medicare to directly negotiate the prices of certain single-source medications without generic or biosimilar competition. CMS selected 10 drugs for an initial round of negotiations in 2023. These included medications for diabetes, heart failure, and peripheral artery disease. These negotiated prices, the highest that a Medicare Part D beneficiary or plan sponsor will have to pay for targeted medications, are slated to go into effect on January 1, 2026. While ASCP and NCPA fully support ensuring fair medication prices for Medicare beneficiaries, an analysis conducted for NCPA found that under MFP, pharmacies may face manufacturer refund payment delays of more than 21 days, beyond the 14-day Medicare prompt pay standard. At the same time, pharmacies could lose nearly $11,000 in weekly cash flow and $43,000 annually. Over 93% of independent pharmacies surveyed by NCPA state they may not be able to stock some medications targeted for price reductions because of cash flow and reimbursement below cost; and most LTC pharmacies anticipate closures, staff layoffs, service reductions, and medications shortages stemming from the MDPNP. Pharmacists at greatest risk for these negative impacts include sole proprietors in rural and urban areas, pharmacies that heavily rely on prescription revenue, and long-term care pharmacies. To address these concerns, ASCP and NCPA made several key recommendations to manufacturers, including the following: 'Most independent pharmacies and long-term care pharmacies care for populations that are heavily dependent on Medicare. It's critical that they are compensated in a fair and timely manner. Otherwise, they will face massive cash-flow problems and not be able to provide prescription services to their Medicare patients. A recent NCPA survey found that 93 percent of independent pharmacists would consider opting out of the program unless those concerns are addressed. That would be a disaster for Medicare beneficiaries and the program itself,' said Doug Hoey, NCPA's CEO. 'The IRA presents unprecedented threats to long-term care pharmacy as well as new opportunities to build a constructive, transactional relationship between pharmacists and manufacturers,' said Chad Worz. 'In developing and presenting these recommendations, we are hoping to send a fair and equitable framework that rekindles the historical partnership between pharmaceutical manufacturers and pharmacies. This, first and foremost, benefits patients while also protecting the sustainability of pharmacies and innovators. We look forward to continuing our constructive conversations with impacted manufacturers.' ASCP and NCPA urge manufacturers to incorporate these recommendations into their MFP effectuation plans by September 1, 2025, ensuring pharmacies remain viable and patients retain access to essential medications. About ASCP: The American Society of Consultant Pharmacists (ASCP) is the only international professional society devoted to optimal medication management and improved health outcomes for all older persons. ASCP's members manage and improve drug therapy and improve the quality of life of geriatric patients and other individuals residing in a variety of environments, including nursing facilities, sub-acute care and assisted living facilities, psychiatric hospitals, hospice programs, and home and community-based care. About NCPA: Founded in 1898, the National Community Pharmacists Association is the voice for the community pharmacist, representing over 18,900 pharmacies that employ more than 205,000 individuals nationwide. Community pharmacies are rooted in the communities where they are located and are among America's most accessible health care providers. Contact Information Melissa Blacketer Senior Director of Communications [email protected] 703-739.1311 SOURCE: ASCP press release
Associated Press
a day ago
- Associated Press
WellBalance to Present Three Sessions at the 2025 IPPA World Congress in Brisbane, Australia
Includes Workshop to Train Coaches and Therapists to Use the WellBalance Model with Clients LAGUNA NIGUEL, CA / ACCESS Newswire / June 12, 2025 / WellBalance is honored to announce its selection to present three sessions at the upcoming International Positive Psychology Association's (IPPA) World Congress, taking place in Brisbane, Australia, July 2-5, 2025. Recognized as the premier global gathering of scientists and practitioners in the field of positive psychology, the IPPA World Congress spotlights cutting-edge approaches to promoting flourishing, resilience, and wellbeing across World Congress 2025 Among hundreds of submissions, three WellBalance abstracts were accepted across diverse formats - including one of only a few workshops offered at the Congress, to train coaches and therapists on the practical application of the WellBalance Model. This high-profile opportunity allows WellBalance to showcase the growing real-world impact of its evidence-based framework for personalized wellbeing design and will form the basis of future of certifications to use the WellBalance Assessment with clients. WellBalance's presentations include: 'This is a tremendous milestone for our team,' said Troy Norris, Founder and Principle Investigator of the WellBalance Institute for Positive Wellbeing. 'To be chosen for multiple presentations - and especially to lead a hands-on workshop for coaches and therapists - demonstrates the relevance, scientific rigor, and practical value of the WellBalance approach to advance the field of positive psychology toward real-world application.' The WellBalance Model and Assessment is a validated psychological measure of positive wellbeing, integrating feelings of wellbeing with lived experiences, to help individuals, coaches, and organizations identify meaningful growth areas and implement tailored, actionable wellbeing plans. The model has been highlighted in peer-reviewed publications in Frontiers in Psychology, Frontiers in Psychiatry, and Advances in the Psychology of Well-Being. This latest recognition by IPPA reinforces WellBalance's commitment to develop practical, science-based strategies to translate the latest science of positive psychology and wellbeing into actionable insights to create more flourishing lives, relationships and workplaces. By integrating validated wellbeing measures with a structured intervention framework, the WellBalance Model of Positive Wellbeing offers individuals, coaches, therapists and employers a practical and personal way to improve positive wellbeing. To learn more about the IPPA World Congress, visit: To explore the science behind the WellBalance Model, visit: Contact InformationTroy Norris Chief Wellbeing Officer SOURCE: WellBalance, LLC press release
Associated Press
2 days ago
- Associated Press
Zentek Announces Test Results Validating ZenGUARD(TM) Enhanced Air Filters as a High-Performance Solution for ASHRAE Standard 241 Compliance
GUELPH, ON / ACCESS Newswire / June 12, 2025 / Zentek Ltd. ('Zentek' or the 'Company') (Nasdaq:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company, is pleased to announce new independent test results comparing the viral filtration efficiency ('VFE') of ZenGUARD™ Enhanced Air Filters against the bacteriophage MS2 compared to equivalent Minimum Efficiency Reporting Value ('MERV')-rated filters without ZenGUARD™. The testing was performed by the third-party ISO 17025:2017 certified lab LMS Technologies Inc. ('LMS'), which specializes in the testing and certification of filter manufacturers across the world in line with American Society of Heating, Refrigerating and Air-Conditioning Engineers ('ASHRAE') standards. Test Results ZenGUARD™ Enhanced Air Filters achieved an average infectious aerosol removal efficiency (εPR) of MS2 bacteriophage of 42% compared to an untreated filter, which achieved an average εPR of 16%. These strong results align with previous tests performed with bacteriophage Phi6, which is often used as a surrogate for SARS-CoV-2 and other enveloped viruses. This milestone adds to a growing body of third-party validation demonstrating ZenGUARD™ Enhanced Air Filter's unique combination of effectiveness and simplicity. To highlight this, the Company believes ZenGUARD™ Enhanced Air Filters are the only technology that can accomplish the following simultaneously: Highly effective at controlling infectious aerosol in line with ASHRAE 241 Achieve this without an increase in pressure drop, energy consumption and carbon emissions Work with existing heating, ventilation, and air conditioning units Not require any additional equipment Extend filter life and reduce changeout frequency compared to more dense filters reducing labour and waste disposal costs ASHRAE Standard 241-2023: Control of Infectious Aerosols ASHRAE Standard 241 is new guidance designed to help buildings reduce the spread of airborne viruses, like SARS-CoV-2, influenza, and other respiratory illnesses. It sets clear guidelines for Equivalent Clean Airflow ('ECA') (from ventilation, filtration, or air cleaning) that is needed to lower the risk of infection in indoor spaces. This is important because it gives schools, offices, and other public buildings a science-based way to improve indoor air quality and the health of building occupants. ASHRAE 241 focuses specifically on health and infection control, making it a key tool for creating safer indoor environments. The standard includes the use of MS2 bacteriophage as a standardized surrogate for evaluating the control of infectious aerosol. Its inclusion ensures a consistent benchmark for assessing the effectiveness of technologies such as ZenGUARD™ Enhanced Air Filters. Based on these new test results using MS2 bacteriophage, the Company now has science-based, directly comparable data demonstrating that ZenGUARD™ is highly effective at controlling infectious aerosols and is fully aligned with ASHRAE Standard 241 testing methodology. ZenGUARD™'s higher εPR translates to a higher ECA, making it a practical and effective option for inclusion in building readiness plans prepared by facility managers and building operators. Importantly, ASHRAE 241 assigns an εPR of zero to any filter rated below MERV 11A. However, ZenGUARD™, which has been independently tested with MS2, can be assigned an EPR of 42%, even when applied to a lower-rated MERV 9A filter. This allows facility managers to confidently adopt ZenGUARD™ technology without needing to upgrade to MERV 11A or higher filters, which may be incompatible with existing HVAC systems. 'These exciting new test results not only reinforce ZenGUARD™'s proven ability to improve indoor quality without increasing energy consumption - they highlight how our solution meets the requirements of ASHRAE 241, the most recent and relevant third-party guidance for controlling infectious aerosols in buildings,' said Greg Fenton, CEO of Zentek Ltd. 'Conventional panel filters - like electrostatically charged MERV 13s - are designed to trap dust and often fall short over time when it comes to impacting aerosols responsible for respiratory infections. In contrast, our filters were specifically designed to enhance mechanical filtration of infectious aerosol via the unique properties of our patented ZenGUARD™ technology - and we have now demonstrated our ability to do this in line with the only standard focused solely on infection control. As building operators face growing pressure to meet new air quality standards and carbon reduction targets, we're proud to offer our unique technology that is proven to effectively keep indoor spaces safe, while also reducing total cost of ownership and carbon emissions.' About Zentek Ltd. Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters Zentek's ZenGUARD™ production facility is in Guelph, Ontario. Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets. For further information: [email protected] Ryan Shacklock Email: [email protected] 306-270-9610 To find out more about Zentek, please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at . Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Zentek Ltd. press release
